Alambic Investment Management’s Myriad Genetics MYGN Stock Holding History

Alambic Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-13,616	Closed	-$402K	–	412
2018 Q1	$402K	Sell	13,616 -89,600	-87%	-$3.03M	0.06%	343
2017 Q4	$3.54M	Sell	103,216 -8,345	-7%	-$282K	0.43%	80
2017 Q3	$4.04M	Sell	111,561 -2,100	-2%	-$59.9K	0.44%	71
2017 Q2	$2.94M	Buy	113,661 +16,400	+17%	+$348K	0.36%	76
2017 Q1	$1.87M	Buy	97,261 +41,200	+73%	+$730K	0.23%	151
2016 Q4	$935K	Buy	56,061 +21,500	+62%	+$389K	0.17%	205
2016 Q3	$711K	Buy	34,561 +23,111	+202%	+$586K	0.17%	213
2016 Q2	$350K	Buy	11,450 +2,250	+24%	+$78.2K	0.09%	353
2016 Q1	$344K	Buy	+9,200	New	+$347K	0.11%	291

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alambic Investment Management's MYGN Position: Q2 2018 in Review

Alambic Investment Management sold out of Myriad Genetics (MYGN) in Q2 2018, closing a stake of 13,616 shares — an estimated $402K sold.

Alambic Investment Management first reported a position in MYGN in Q1 2016 and held it in 9 quarters. The position peaked at $4.04M in Q3 2017. 258 funds tracked by Wall St. Rank hold MYGN as of Q2 2018.

Alambic Investment Management reported no remaining Myriad Genetics position as of Q2 2018 after selling out during the quarter.
Alambic Investment Management sold 13,616 Myriad Genetics shares in Q2 2018, an estimated $402K.
Alambic Investment Management first reported a position in Myriad Genetics in Q1 2016 and held it in 9 quarters.
Alambic Investment Management's Myriad Genetics position peaked at $4.04M in Q3 2017.
258 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2018.

Based on Alambic Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.